NEW YORK – Illumina said on Friday that it has completed its acquisition of SomaLogic and other assets from Standard BioTools.

纽约——Illumina周五表示，已完成从Standard BioTools收购SomaLogic及其他资产。

Illumina paid $350 million in cash, subject to customary adjustments. The deal also includes up to $75 million in near-term performance-based milestones and performance-based royalties.

Illumina支付了3.5亿美元现金，视惯例调整而定。该交易还包括高达7500万美元的近期基于绩效的里程碑款项和基于绩效的特许权使用费。

Among the other assets is Krex antibody profiling technology, originally developed by

其他资产中包括Krex抗体分析技术，该技术最初由

Sengenics

Sengenics

, which Standard BioTools

，标准生物工具

acquired

获得

in 2024. At that time, the firm said it would add the Krex technology to its SomaScan platform.

2024年。当时，该公司表示会将Krex技术添加到其SomaScan平台中。

Illumina said it would discuss the implications of the transaction next week when it presents its fourth-quarter and full-year 2025 financial results.

Illumina表示，将在下周公布其2025年第四季度和全年财务业绩时，讨论该交易的影响。

Under the deal, announced in June 2025, Standard BioTools will receive payments for assay services and sales of certain sequencing library preparation and array kits in fiscal years 2025 and 2026, as well as a 2 percent royalty on net revenues for 10 years.

根据2025年6月宣布的协议，Standard BioTools将在2025和2026财年获得某些测序文库制备和阵列试剂盒的检测服务及销售收入，并在十年内获得净收入2%的特许权使用费。

Illumina will obtain facilities in Boulder, Colorado, including a CLIA- and CAP-certified lab. 'We have no immediate plans to change operations in Boulder and will leverage our global presence and operations expertise around the world to serve customers,' a spokesperson for the firm said in an email..

Illumina将获得位于科罗拉多州博尔德的设施，包括一家CLIA和CAP认证的实验室。该公司的一位发言人在电子邮件中表示：“我们目前没有计划改变博尔德的运营，将利用我们的全球影响力和世界各地的运营专业知识来服务客户。”

Illumina had already struck a

Illumina 已经达成了一个

codevelopment deal

共同开发协议

with SomaLogic prior to its acquisition by Standard BioTools to develop a sequencing-based readout for the SomaMer DNA aptamer-based protein detection technology. Illumina launched the technology as its Protein Prep assay in September.

在SomaLogic被Standard BioTools收购之前，与之合作开发基于测序读取的SomaMer DNA适配体蛋白质检测技术。Illumina于九月将该技术作为其Protein Prep检测推出。